

Date: May 9, 2025

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 40 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 (“the Listing Regulations”)

We wish to inform you that the Company has received orders from Office of the Dy. Commissioner of Income Tax, Central Circle 29, New Delhi dated 1st May, 2025 for AY 2014-15 to AY 2019-20 & AY 2021-22 in relation to M/s. Lifestar Pharma Private Limited, merged with M/s. Mankind Pharma Limited (Received on 8th & 9th May, 2025 through IT Portal) and dated 7th May, 2025 for AY 2014-15 to AY 2019-20 & AY 2021-22 in relation to M/s. Magnet Labs Private Limited, merged with M/s. Mankind Pharma Limited (received on 9th May, 2025 through IT Portal).

The detailed disclosure required as per Regulation 30 of the Listing Regulations read with Master Circular No. SEBI/HO/CFD/ PoD2/CIR/P/0155 dated November 11, 2024 as amended from time to time is enclosed herewith as Annexure-I.

This is for your kind information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary and Compliance Officer

Encl: as above

**ANNEXURE-I**

Sr. No.	Details of event that needs to be provided	Details
1	Name of the authority	Office of the Dy. Commissioner of Income Tax, Central Circle 29, New Delhi ('IT Authority')
2	Nature and details of the action(s) taken, initiated or order(s) passed;	- AY 2014-15 to AY 2019-20 & AY 2021-22 (M/s. Lifestar Pharma Private Limited, merged with M/s. Mankind Pharma Limited) - AY 2014-15 to AY 2019-20 & AY 2021-22 (M/s. Magnet Labs Private Limited, merged with M/s. Mankind Pharma Limited)
3	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority;	Orders dated 1 st May, 2025 for AY 2014-15 to AY 2019-20 & AY 2021-22 in relation to M/s. Lifestar Pharma Private Limited, merged with M/s. Mankind Pharma Limited (Received on 8 th & 9 th May, 2025 through IT Portal) Orders dated 7 th May, 2025 for AY 2014-15 to AY 2019-20 & AY 2021-22 in relation to M/s. Magnet Labs Private Limited, merged with M/s. Mankind Pharma Limited (Received on 9 th May, 2025 through IT Portal)
4	Details of the violation(s)/contravention(s) committed or alleged to be committed;	The IT Authority vide reassessment orders has raised additional tax demand (including interest) of INR 128.25 crores under Section 147 read with Section 143(3) of the Income-tax Act, 1961 ('the Act') on account of disallowance of various expenditures u/s 37(1) of the Act.
5	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible;	The Company believe that the demand under the above referred Orders is not tenable in law. The Company has adequate factual and legal grounds to substantiate its position and does not expect any material impact on financials or operations of the Company due to the said orders. The Company would pursue appeal against the said orders under the applicable laws.

MANKIND PHARMA LIMITED